<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04007146</url>
  </required_header>
  <id_info>
    <org_study_id>2019-002571-33</org_study_id>
    <nct_id>NCT04007146</nct_id>
  </id_info>
  <brief_title>Systematic Calculation of HyperOxygenation Transit Time</brief_title>
  <acronym>SCHOTT</acronym>
  <official_title>Systematic Calculation of HyperOxygenation Transit Time Mesure transcutanée de l'oxygène au Cours de l'Hyperoxie Transitoire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac output (CO) is an essential physiological parameter of healthy person or illness.

      In clinical practices, all methods of measuring the CO(Fick method, thoracic impedance,
      esophageal echodoppler etc) contain limit. Each method are dangerous or hard to implement.

      CO is probably determining element of blood transit time and thus the availability of oxygen
      between the central organs (heart, lung) and the peripheral organs (leg, arms).

      Our hypothesis is transcutaneous oxymetry mesurement with oxygen inhalation, to cause a
      transient hyperoxia, can be used to determinate blood transit time between central organs and
      peripheral organs. This simple method will be non invasive technique.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At admission eligible patients are proposed to participate. Written consent is signed after
      complete oral and written explanation of the protocol is signed.

      The time of onset hyperoxia will be compare to usual CO method by cross correlation.

      The duration of participation for subject is equal to 1 hour.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of transcutaneous oxymetry with transient hyperoxia</measure>
    <time_frame>24 months</time_frame>
    <description>Transition time calcutation from oxygen to peripheral organs by transcutaneous oxymetry method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average of CO measured</measure>
    <time_frame>24 months</time_frame>
    <description>Average of CO by usual method (catheterisation or transoesophageal echocardiography) reported in medical record of patients</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cardiac Output</condition>
  <arm_group>
    <arm_group_label>Cardiac Output Measurement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will have a usual cardiac output</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Transcutaneous oxymetry measurement</intervention_name>
    <description>Transcutaneous oxymetry measurement with transient hyperoxia period (2 periods of 30seconds at 60% of oxygen)</description>
    <arm_group_label>Cardiac Output Measurement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults over 18

          -  Cardiac output measurement considered at least 2 hours prior to the study

          -  Affiliation to a French National healthcare system

          -  Written informed consent must be obtained prior to protocol-specific

        Exclusion Criteria:

          -  Acute or decompensated cardiac or respiratory failure

          -  Allergy to medical adhesives

          -  Patients under reinforced protection, pregnancy, deprived of liberty by judicial or
             administrative decision, hospitalized without consent or admitted to a health or
             social establishment for purposes other than research

          -  Inability to understand the instructions or objectives of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre MD ABRAHAM, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital in Angers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre ABRAHAM, PhD</last_name>
    <phone>241353610</phone>
    <phone_ext>+33</phone_ext>
    <email>piabraham@chu-angers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marine MAUBOUSSIN</last_name>
    <phone>668047430</phone>
    <phone_ext>+33</phone_ext>
    <email>marine.mauboussin@chu-angers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre hospitalier universitaire</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Abraham, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre Abraham, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>July 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac Output</keyword>
  <keyword>vascular medicine</keyword>
  <keyword>Transcutaneous Oxymetry</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

